The RP HealthCast

In today’s podcast, we examine mental well-being during COVID-19, how society is coping, and the long-term ramifications of the pandemic. Full year of the pandemic and the rolling lockdowns was hard on all of us. And it brought the subject of mental wellness to center stage. The pandemic led to isolation. For others, it was joblessness and more.

Digital technology companies are looking to solve some of the world’s largest healthcare issues such as diabetes, congestive heart failure, obesity and Alzheimer’s. In this episode we speak with experts on the front line of blending technology with healthcare and social change.

This episode explores how artificial intelligence and machine learning allow biopharmaceutical companies to quickly and cost-effectively bring new products to market.  This exciting new technology unlocks the door for discovering therapies in rare diseases and other unmet medical conditions that were once too costly and time consuming to develop.

The RP HealthCast is back! In our season two premiere, we speak with a scientist, researcher, and medical journalist about the devastating effects experienced by “long-haulers” — a growing group of people who still suffer from COVID-19 symptoms months after being infected.

The RP HealthCast returns in 2021 with a fresh format, featuring captivating stories from innovators, journalists, medical professionals, and more!

In each episode our host, Jeffrey Freedman, goes beyond the headlines to explore different perspectives and discuss varying viewpoints on the latest advancements in technology and health.

Please stay tuned for our first episode premiering next week.

In this week’s episode, we speak with Zachary Brennan of Politico about the newly approved coronavirus vaccines, their distribution plans, and how these advances are poised to change the course of the pandemic.

In this week’s episode, we speak with Dr. Cathy Faye, the Executive Director of the Cummings Center for the History of Psychology at the University of Akron, about how dangerous unsubstantiated rumors and misinformation can be to society — especially in the context of a global pandemic.

In this week's episode, we speak with medical journalist, Charlotte Huff, about the mental and physical hardships that nurses are facing as the coronavirus pandemic appears to be entering its deadliest phase. 

In this week’s episode, we speak with Lisa Gill from Consumer Reports about the ever increasing trend of unpaid medical debt in America. Lisa discusses real-life scenarios, what to look for on your bills, what to ask for when getting treatment, and who you can go to if you get overburdened with costs.

In this week’s episode, we speak with Brandon May, a NYC-based medical journalist and writer, about how the healthcare industry has had to quickly evolve to meet the needs of patients during the pandemic.

In this week’s episode, we speak with Elizabeth Bernstein of The Wall Street Journal about how to strengthen and nurture our relationships with family, friends, and even ourselves during these turbulent times.

In this week’s episode we speak with Lauren Young from Reuters about technology and working from home. Depending on your stage of life, your family situation and your access to technology, remote work has required quite a significant learning curve, and, in some cases, it presents a hardship

In this week’s episode we speak with Monique Brouillette, from Scientific American who explains the varying stages a patient may go through after contracting the novel coronavirus — and the importance of receiving the proper treatment at each critical phase.

In this week’s episode we speak with Kimberly Leonard, senior reporter for Business Insider, about the upcoming Supreme Court hearing on the constitutionality of the ACA and what the ruling could mean for the US healthcare system.

In this week’s episode we speak with science writer, author, educator and photojournalist, Tara Haelle, to discuss the vaccine approval process and how political meddling could undermine the public’s perception of a coronavirus vaccine and their willingness to get it.

In this week's episode, we speak with Andrew Dunn from Business Insider to discuss the COVID vaccine timetable; who are the players, who are the front runners, and when will a vaccine be made available to the general public.

In this week’s episode we speak with Larry Light, editor for Chief Investment Officer and writer for Forbes.com, to discuss how the current political and economic turbulence influence the markets and what socioeconomic variables create the largest volatility.

Brian Bremner, Executive Editor of Global Business for Bloomberg News discusses how the largest countries in the world have responded to the pandemic. With the US having more than 20% of the deaths worldwide, what are we doing wrong in containing COVID-19, and which countries are leading the way in doing it right?

In this week’s episode we speak with Claudia Wallis, an award-winning health journalist for Scientific American, about what it is about a person’s genetic make-up that could make them more at risk to COVID-19 than others.

While still categorized as a Schedule 1 substance—and not approved by the FDA—some form of cannabis is legal in more than 60% of the country. In this week’s episode, we speak with Anthony Noto from Benzinga, where he gets into the weeds of this multi-billion dollar industry and the issues it faces.

Money’s senior healthcare writer Elizabeth O’Brien explains the difference between diagnostic and antibody tests and the advances that newer iterations need to make when it comes to speed and accuracy.

In this week’s episode, we speak with Erin Griffith of The New York Times about the impact of the pandemic on start-up activity and the VC community.

In this week’s episode we speak with public school teacher Rebecca Martinson on why she won’t risk the health and safety of her family by going back into live classroom teaching.

In this week's episode we’re joined by Jan Benzel, a 30-year veteran of the New York Times, who chronicled the miraculous survival of one of New York's early COVID patients, Larry Kelly, and how his journey mirrored that of the city in which he lives.

In this week's episode, Michael Brown, co-editor of The Deal, and veteran financial reporter Charlie Paikert discuss the pandemic’s impact on corporate mergers and acquisitions.

We talk with our guest this week, Julie Hyman of YahooFinance, about companies big and small having to manage their businesses and employees around the complexities of the coronavirus—and now finally—a larger focus on social justice issues.

Melinda Wenner Moyer writes a column for Slate and is a contributing editor at Scientific American magazine – she writes for the New York Times, Mother Jones, and a number of women’s magazines.

Misinformation about COVID-19 seems to spread faster than microbes. In this episode, Emmy-award winning journalist, author, professor and epidemiologist, Dr. Seema Yasmin, helps separate the fact from the fiction.

As the United States continues to see record-breaking new coronavirus cases, the country's reopening has become one of today's most critical topics. We discuss the issue with Forbes' reporter Alexandra Sternlicht and examine the unsettling resurgence, complications with testing, and the disproportionate impact of the virus on communities of color.

In this week's episode, journalist Christina Farr gives her shortlist of the companies to watch from CNBC's Disruptor 50, relays riveting first-hand accounts from heroes on the front lines of the pandemic, and weighs in on why the road to effective contract tracing in the United States is proving to be a not-so-simple path.

Biotechs around the world are sprinting to develop a viable coronavirus vaccine. But which will get to the finish line first? In this episode, Business Insider's healthcare reporter Andrew Dunn takes us through the myriad of concurrent trials taking place and what this all means for potentially changing the course of the pandemic.

In this week's episode we speak with Bailey Lipschultz of Bloomberg to discuss the outlook for the biotech industry and the industry's recent winners and losers in these turbulent markets.

In this week’s interview we speak with Shawn Tully, Senior Editor At Large for Fortune Magazine, where we discuss the intersection of public policy, public health and government spending as it relates to the coronavirus and the huge cost we are shouldering by keeping the economy closed.

In this week’s episode, we speak with Sara Harrison of Wired.  Sara discusses the issues our senior population have with the coronavirus and why they are more at risk for serious health complications than the rest of us.

In this week’s episode, we speak with Maria Aspan, senior writer for Fortune, where we discuss the risks and sometimes fatal results stemming from breast augmentation surgery, and we explore where the responsibilities lie for protecting the millions of woman who have had this surgery and educating those women who are exploring the surgery for the first time.

In this week's episode we speak with Brian Bremner, Executive Editor, Global Business at Bloomberg, where we talk about the global aspects of the Covid-19 pandemic and the politics behind finding a cure, creating a vaccine and ultimately could government policy effect the global distribution of that vaccine.

In this week's episode, we speak with Tiernan Ray, a freelance journalist who writes for ZDnet, the Street.com and other publications, about healthcare technology innovation including the power of artificial intelligence - its pace of development and where it may lead us in the 21st century and beyond.

In this episode, we speak with Sue Karlin, who is an expert, and recent writer of an article for Fast Company magazine on the science behind and the importance of face masks.

Business Insider's Lydia Ramsey shares how she covers the pandemic while living in one of its epicenters, the way hospital systems are handling the crisis, and new forms of doctor/patient communication.

In this episode, we speak with Edward Baig, a veteran technology journalist and former USA Today columnist about new technology, Contact Tracing, that will enable America to get back to work as we come out of the grips of this pandemic

An interview with Kevin Chupka, Executive Producer at Yahoo Finance. We talk to Kevin about the differences and power of the Internet as a news media, with viewers expectations of a real-time, always-on reporting and coverage cycle versus how that may differ from other media, and how very important this is during a pandemic.

In this week's episode, we speak with Eric Savitz of Barron's about some of the recent stories he’s written on the effects of the pandemic on the financial markets - as well as on companies that are innovating and creating technology to better enable us to work more effectively from home.

In this week’s podcast, we speak with Dan Colarusso, SVP of CNBC, who discusses how they transformed their daily newsroom to a new world of remote broadcasts and social distancing.

Our Guest this week is Paul Sullivan of The New York Times. Paul is the Wealth Matters columnist. COVID-19 has created havoc within our society from a healthcare point of view, where today we have over half a million Americans with the virus and over twenty-five thousand fatalities. As we are entrenched now for the long-haul, we thought it would be very interesting to hear from someone that has been monitoring the economic fallout from the pandemic and how it has been impacting companies of all sizes. 

A weekly podcast series that discusses the latest advancements and innovations in medicine and healthcare. 

The series will explore the stories and value propositions of the companies shaping the future of medicine.  To learn about these stories, we thought it best to hand over the microphone to those who are building and writing about the future.

Therefore, we will be speaking with journalists at the forefront of healthcare reporting as well as the leaders of companies behind the latest breakthroughs in medicine and technology, and discuss the impact these companies have in today’s society to see how they benefit or make a difference in people’s lives.